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Abstract
Background—The basis for increased mortality after heart transplantation in African Americans 
and other non-Caucasian racial groups is poorly defined. We hypothesized that increased risk of 
adverse events is driven by biological factors. To test this hypothesis in the IMAGE study, we 
determined whether the event rate of the primary outcome of acute rejection, graft dysfunction, 
death, or re-transplantation varied by race as a function of calcineurin inhibitor levels and gene 
expression profile (GEP) scores.
Methods—We determined the event rate of the primary outcome, comparing racial groups, 
stratified by time post-transplant. Logistic regression was used to compute the relative risk across 
racial groups and linear modeling was used to measure the dependence of CNI levels and GEP 
score on race.
Results—In 580 patients followed for a median of 19 months, the incidence of the primary 
endpoint in African Americans, other non-Caucasians, and Caucasians was 18.3%, 22.2%, and 
8.5%, respectively (p<0.001). There were small but significant correlations of race and tacrolimus 
trough levels to GEP score. Tacrolimus levels were similar between races. Of patients receiving 
tacrolimus, other non-Caucasians had higher GEP scores than the other racial groups. African 
American recipients demonstrated a unique decrease in expression of the FLT3 gene in response 
to higher tacrolimus levels.
Conclusions—African Americans and other non-Caucasian heart transplant recipients were 
2.5–3 times more likely than Caucasians to experience outcome events in IMAGE. The increased 
risk of adverse outcomes may be partly due to the biology of the alloimmune response, which is 
less effectively inhibited at similar tacrolimus levels in minority racial groups.
Keywords
Heart transplantation; race; acute rejection; mortality
INTRODUCTION
Racial disparities in survival after solid organ transplantation were first recognized by Opelz 
and Terasaki in 1977, when large differences between African American and Caucasian 
recipients were identified after kidney transplantation.(1) Since then, multiple reports have 
demonstrated worse survival after heart transplantation in African American recipients, 
compared to other racial groups.(2–7)
Many reasons have been suggested to account for racial disparities in post-transplant 
outcomes. These include socioeconomic and educational factors,(2) access to high-quality 
medical care,(4) compliance, a higher prevalence of co-morbidities such as hypertension in 
African American recipients,(8) and fundamental immunologic differences.(9, 10)
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The Invasive Monitoring Attenuation through Gene Expression (IMAGE) study,(11) which 
examined the clinical utility of monitoring for acute rejection after heart transplantation 
using peripheral blood gene-expression profiling, provided a unique opportunity to study the 
biology of racial differences in heart transplant outcomes. We sought to determine whether 
the incidence of acute rejection, graft dysfunction, death, or re-transplantation varied 
according to race, and to elucidate observed racial disparities in outcomes on the basis of 
immunosuppressive (calcineurin-inhibitor, CNI) drug levels and peripheral blood gene-
expression patterns.
METHODS
Study design, patients, and procedures
The IMAGE study was a randomized trial conducted at 13 U.S. heart transplant centers 
between January 2005 and October 2009. The study design and procedures have been 
described previously.(11, 12) Adult heart transplant recipients, between 6 months and 5 
years after transplant, were eligible for enrollment and were randomly assigned to undergo 
monitoring for rejection by means of gene-expression profiling (GEP) or routine 
endomyocardial biopsies (EMB). Patients assigned to the EMB group also had blood 
samples taken for GEP testing.
This study population (n = 602) was comprised of 12% African Americans and 6% other 
non- Caucasian participants, and compliance with medical therapies and rejection 
surveillance was closely monitored throughout the study period by trial coordinators. Data 
on medications and laboratory results enabled us to examine differences in 
immunosuppressive drug doses and CNI trough blood levels between racial groups. Finally, 
data on composite gene expression (AlloMap) scores and expression of each of the 11 genes 
comprising this test were available. These individual genes were originally selected to 
distinguish immune activation associated with acute rejection from a quiescent state. 
Analysis of IMAGE study data thereby enabled us to correlate clinical outcomes in different 
races with individual gene expression, which may provide insight into the biology of racial 
differences in transplant outcomes.
Gene-expression testing was performed with the use of the AlloMap test (CareDx), which 
evaluates expression levels of 11 informative genes that were shown in previous studies to 
distinguish between rejection and the absence of rejection.(13) Possible scores range from 0 
to 40, with higher scores indicating a higher likelihood of histologic rejection. Patients were 
followed for a maximum of 24 months, until they died or until the study completion date, 
whichever occurred first.
Outcomes
The primary IMAGE trial outcome was the first occurrence of rejection with hemodynamic 
compromise, graft dysfunction due to other causes, death, or re-transplantation. Rejection 
with hemodynamic compromise was defined as one or more of the following criteria: 
absolute drop in left ventricular ejection fraction (LVEF) ≤ 30%, proportional decrease in 
LVEF≥25% compared to the first study visit, cardiac index < 2 L/min/m2, and/or use of 
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inotropic drugs to support circulation at the time of the rejection episode. Death from any 
cause was considered as a secondary outcome.
Statistical Analysis
For the current analysis, 580 patients who had at least one Allomap score were studied. The 
patients were assigned to one of three groups based on self-identified race: Caucasian, 
African American, and other non-Caucasian, where the other non-Caucasian category 
includes predominantly Hispanic, Asian, and Pacific Islander populations. Within each 
group, study visits were classified by the time period post-transplant: 7 – 12 months, 13 – 36 
months, and greater than 36 months. Demographics (age, racial group, CMV status, and 
number of rejections in the first year) of each racial group were assessed for the subset of 
patients with visits in each time period. CMV status was coded as a binary variable: 1 for 
donor positive/recipient negative and 0 otherwise. For demographic variables, each of three 
pairwise comparison between the racial groups were performed, using Tukey’s test for 
continuous variables and Fisher’s test with correction for multiple hypothesis testing via the 
Bonferroni method for discrete variables.
Racial differences in event rates—Event-free progression after study entry, within 
each racial group, was assessed using Cox modeling. Event rates and death rates for each 
racial group in each time period were calculated by dividing the total number of events 
observed during that time by the total length of time patients were followed.
Racial differences in calcineurin inhibitor levels—Only visits at which patients 
were taking a calcineurin inhibitor (CNI), either tacrolimus or cyclosporine, were included. 
CNI trough levels for each patient’s visits falling within a particular time period were 
averaged to generate a summary for that patient and time period. Then, the patient averages 
were summarized across each racial group. When comparing drug levels between racial 
groups, pairwise comparisons, overall and within the 1 to 3 year time period, were 
performed using Tukey’s test. We chose to focus on years 1 to 3 post-transplant since most 
study visits occurred during this time period.
Doses of prednisone greater than 20 mg per day and those administered for treatment of 
acute rejection were excluded from analyses of maintenance corticosteroid dosing.
Racial differences in gene expression profile scores—GEP scores for patient visits 
falling within a particular time period were also averaged to generate a summary for that 
patient and time period; patient averages were then summarized across each racial group. To 
compare GEP scores between racial groups, pairwise comparisons, overall and within the 1 
to 3 year time period, were performed using Tukey’s test.
To study the determinants of GEP score, a multivariate model was fit on patients treated 
with tacrolimus (n = 435), with tacrolimus trough level, prednisone dose, racial group, time 
post-transplant, age, sex, and CMV status as predictors. Univariate models were used to 
study associations between tacrolimus levels and each of the 11 gene components of the 
GEP score, both overall and within each racial group.
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RESULTS
Patients
A total of 602 patients were enrolled in the IMAGE trial and 580 patients who had at least 
one GEP score were included in the current analysis. Caucasians comprised the majority of 
patients (78%), followed by African Americans (11%), and other non-Caucasians (11%). 
Baseline characteristics of the study population are presented in Table 1. Caucasian patients 
were older and were enrolled later (>1 year post-transplant) compared to the other racial 
groups. African American patients had a higher prevalence of diabetes, were less likely to be 
bridged to transplant with a left ventricular assist device (LVAD), and were more often 
randomized to the endomyocardial biopsy arm of the IMAGE study for rejection 
surveillance. Between-group comparisons of recipient sex, age, prevalence of CMV 
mismatch (CMV donor +/recipient −), and mean number of rejection events during the first 
year post-transplant revealed age as the only significant difference, with other non-
Caucasians being younger than Caucasians. There were no significant differences in the 
percentage of patients treated with mycophenolate mofetil and maintenance corticosteroids 
between the three racial groups.
Racial differences in event rates
Comparison of freedom from the primary endpoint (Figure 1) demonstrates significant 
differences between the three racial categories (p=0.001 for Caucasian vs. African 
American; p<0.001 for Caucasian vs other non-Caucasian). Specifically, Caucasians had the 
highest probability of event-free progression [HR 0.87 (95% CI 0.81–0.91)] compared to 
African- Americans [HR 0.74 (0.57–0.85)], and other non-Caucasians [HR 0.70 (0.54–
0.82)]. These results were consistent after adjusting for transplant center, recipient age and 
sex, use of pre-transplant LVAD, and CMV status (Supplemental Table 1).Table 2 
summarizes the event rates of the composite outcome, as well as death, stratified by racial 
group and time post-transplant. The overall event rate and the death rate were, in general, 
higher in the African American and other non-Caucasian groups, compared to Caucasian 
transplant recipients.
Racial differences in calcineurin inhibitor levels
More patients were treated with tacrolimus (n = 435) than cyclosporine (n = 156). 
Tacrolimus was used more commonly for maintenance immunosuppression in Caucasian 
and African American recipients, whereas the choice of CNI was more balanced in other 
non-Caucasians (Table 2). A comparison of median calcineurin inhibitor trough levels 
demonstrated significantly higher cyclosporine levels and lower tacrolimus levels in other 
non-Caucasians compared to Caucasians. There were no significant differences in 
tacrolimus or cyclosporine trough levels between African American and Caucasian patients.
Racial differences in gene expression
We compared mean gene expression profile (GEP) scores between racial groups, as a 
function of time post-transplant and type of calcineurin inhibitor used for maintenance 
immunosuppression. As demonstrated in Table 2, GEP scores were overall similar between 
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the three racial groups, with the following exceptions: African Americans treated with 
cyclosporine had higher GEP scores than Caucasians and other non-Caucasians treated with 
cyclosporine; and, among tacrolimus-treated patients, other non-Caucasians had 
significantly higher GEP scores than the other two racial groups between 1 and 3 years post-
transplant (p-value <0.001 for Caucasian vs other non-Caucasian; p-value 0.004 for African 
American vs other non-Caucasian).
We then examined determinants of the GEP score to identify factors that may contribute to 
differences in gene expression in the study population. In multivariate models 
(Supplemental Table 2), recipient race, transplant center, and CMV status were significantly 
correlated with the overall GEP score.
As a next step, we studied associations between tacrolimus levels and expression levels of 
the 11 individual genes that are used in the computation of the AlloMap ordinal score (Table 
3). In the overall study cohort, increasing tacrolimus levels were associated with 
downregulation of MARCH8 (p<0.001) and WDR40A (p=0.004), genes that mediate 
hematopoiesis; and upregulation of ITGAM (p=0.005), a gene expressed by monocytes that 
mediates responsiveness to corticosteroids. These associations were mainly driven by 
changes in Caucasian recipients, who comprised a majority of the patient population. 
African American recipients demonstrated a unique decrease in expression of the FLT3 
gene, which promotes B-cell and NK-cell proliferation, in response to higher tacrolimus 
levels (p=0.002) (Supplemental Table 3); however, this association was attenuated after 
adjusting for transplant center as well as recipient age, sex, pre-transplant LVAD, and CMV 
status (p=0.06).
Finally, we compared differences in individual gene expression between Caucasian and 
African American study participants. We found significantly increased expression of 
MARCH8 (p=0.001), and decreased expression of FLT3 (p=0.0002), and PDCD1 (p=0.002) 
in African Americans compared to Caucasians, even after correction for multiple hypothesis 
testing. FLT3 and MARCH8 expression were significant predictors of clinical events in 
African American subjects, even after adjusting for relevant covariates (Table 4).
DISCUSSION
We used data from the IMAGE trial, a prospective randomized clinical trial of peripheral 
blood gene-expression profiling versus endomyocardial biopsy for cardiac transplant 
rejection surveillance, to examine racial differences in post-transplant outcomes. 
Specifically, we used this unique data set to test the overall hypothesis that the increased risk 
of adverse events seen in non-Caucasian minority racial groups is driven by biological 
factors related to the alloimmune response.
As is consistent with prior studies,(2, 5) we found a higher incidence of the primary outcome 
(rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or 
retransplantation) in African Americans and other non-Caucasians, compared to Caucasian 
trial participants. Previous work studying transplant outcomes have suggested that access to 
medical care and compliance with immunosuppressive medications may mediate the 
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discrepancies in outcomes seen between racial groups.(2, 4) Other studies, however, have 
shown that universal access to medical care (e.g. via the Veterans Administration healthcare 
system) does not eliminate racial disparities in transplant outcomes.(14) A clinical trial such 
as IMAGE therefore offers a unique opportunity to address this controversy: all patients 
were treated at major academic medical centers and were followed closely by medical staff 
and trial coordinators. Compliance was monitored in the context of trial participation, and 
immunosuppressive drug levels were followed closely. Indeed, few differences were seen in 
immunosuppressive drug levels between racial groups, suggesting that access to care and 
compliance were not major factors contributing to the disparity seen in the incidence of 
adverse post-transplant outcomes.
Immunologic differences between transplant recipients of distinct racial groups may play an 
important role. (6) Indeed, in tests of immune function such as mixed lymphocyte reactions 
and T helper:T suppressor cell ratios, African Americans were more likely than Caucasians 
to be strong responders.(8, 15, 16) Studies such as those published by Mehra in 2002,(17) in 
which African American heart transplant recipients treated with tacrolimus had greater 
freedom from rejection at 1-year post-transplant than those treated with cyclosporine suggest 
that more potent immunosuppressive therapies(18, 19) may attenuate the effects of racial 
differences in alloreactivity. Adding to this argument is the clinical observation that 
induction therapy with both monoclonal and polyclonal antibodies enhances outcomes in 
African American kidney transplant recipients,(20) who also appear to be more resistant 
than Caucasians to developing complications such as opportunistic infections.(21)
The immunological differences between races may result from a combination of influences. 
First, the genetic diversity of human leukocyte (HLA) antigens in African Americans, and 
the relative scarcity of African American donors, makes it likely that African Americans 
recipients will receive poorly HLA-matched hearts. Second, the expression of T-cell 
costimulatory molecules CD80 and CD86, which are necessary for T-lymphocyte activation 
during the alloimmune response, is higher in African Americans than Caucasians.(10) 
Finally, purified T cells from African American subjects demonstrate significantly increased 
proliferation to phytohemagglutinin compared to those from Caucasians.(10) Thus, racial 
variations in peripheral blood antigen presenting cell characteristics may contribute to 
disparities in allograft rejection rates.
Upon analyzing data from IMAGE, we found similar GEP scores between racial groups, 
stratified by time post-transplant. This result supports the theory that current standard 
immunosuppressive therapies, such as tacrolimus and mycophenolate mofetil, may diminish 
immunologic differences between races. Notable exceptions were the higher GEP scores 
seen in African American recipients treated with cyclosporine, which is considered to be 
less effective than tacrolimus in the prevention of heart transplant rejection in all races.(22, 
23) This finding is consistent with the observation that African American patients in 
IMAGE who were treated with cyclosporine had a higher incidence of the primary outcome 
compared to those treated with tacrolimus (6/10 vs. 6/50, respectively, p=0.0015), and lends 
support to other clinical trials that have shown a higher incidence of rejection in African 
American recipients treated with cyclosporine.
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In multivariate analysis, race was not a significant predictor of the GEP score. Tacrolimus 
level was a significant predictor, however. In univariate models, increasing tacrolimus levels 
were significantly associated with up- or down-regulation of individual genes in the 11-gene 
panel. We therefore conducted an exploratory analysis to examine the association of 
tacrolimus levels with expression of these individual genes, stratified by race. A decrease in 
FLT3 gene expression was uniquely seen in the African American sub-group, despite the 
relatively small size of this cohort, and was an independent predictor of clinical events in 
this group. This gene is primarily expressed in immature hematopoietic progenitor cells in 
the bone marrow, and the gene product (fms-related tyrosine kinase receptor or CD135) is a 
cell surface receptor for FLT3 ligand—a factor produced by bone marrow stem cells that 
acts in collaboration with growth factors and cytokines to stimulate the proliferation of stem 
cells, B-cells, dendritic cells, and NK-cells.(24–26) Although speculative, we hypothesize 
that downregulation of FLT3 in African American transplant recipients may contribute to 
the differential outcomes seen in this racial group, despite similar tacrolimus levels, 
corticosteroid doses, and overall GEP scores, when compared to Caucasians. The biology of 
FLT3 downregulation in this context requires further investigation, and may contribute to 
our understanding of the biology of racial differences in transplant outcomes.
This work has significant strengths and limitations. The association between African 
American race and poorer post-transplant outcomes, including an increased incidence of 
acute rejection and decreased survival, has long been recognized. Theories to account for 
this disparity have abounded, and have included socioeconomic and biological causes. 
Unfortunately, these etiologies cannot be further investigated in the context of registry 
analyses or retrospective observational studies. Within the framework of clinical trials such 
as IMAGE, which involve rigorous monitoring of study subjects, differences in access to 
care and follow-up are likely to be minimized. If present, race-based differences in outcomes 
are therefore more likely to reflect biological or genetic responses to immunosuppressive 
therapy, and such trials offer a unique opportunity to study these mechanisms. The close 
patient follow-up required by IMAGE, with rigorous documentation of drug doses and 
levels, adjudication of endomyocardial biopsy results and clinical events, and serial gene 
expression scores, enabled us to begin studying these biological differences. We were not, 
however, able to adjust for traditional markers of poor outcomes such as education and 
socioeconomic status in our analyses, as data on these variables were not collected in 
IMAGE. We were also unable to adjust for all patient covariates that may have accounted 
for differences in GEP scores between transplant centers. These include differences in racial 
distribution and demographic characteristics between centers, treatment strategies (e.g. 
induction immunosuppression, corticosteroid weaning), and patient characteristics (medical 
severity, degree of allosensitization). There were also significant between-center differences 
in timing of patient enrollment, as some centers started enrollment at 6-months post-
transplant, whereas other centers enrolled patients at a median of 3-years post-transplant. An 
additional limitation is that the 11-gene GEP tool was developed in the CARGO (Cardiac 
Allograft Rejection Gene Expression Observational) study,(13) which enrolled 72% 
Caucasians. It is possible that this panel may be best suited to Caucasian recipients, and that 
other genes may be more relevant to non-Caucasian heart transplant recipients. We finally 
acknowledge that IMAGE study patients were felt to be at lower risk of rejection than the 
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heart transplant recipient population in general, as those with a history of antibody mediated 
rejection or recent acute cellular rejection were excluded from enrollment. This represents a 
selection bias of the original trial and therefore of any subsequent analyses.
While conducting studies such as this, it is important to recognize that race is an imperfect 
and ill-defined descriptor that encompasses important social, economic, and genetic 
differences. The African American race is highly genetically diverse, with historical roots in 
Western and Central Africa, the Caribbean, Central America, South America, and Europe. In 
fact, it is estimated that current African Americans inherit approximately 14–18% of their 
ancestry from Europeans,(27) thereby casting doubt on the utility of racial distinctions when 
examining clinical outcomes. Nevertheless, these terms are commonly used in clinical 
practice today and may help, albeit imperfectly, to tailor post-transplant therapies. In 
addition, we found a significantly higher incidence of the primary outcome in other non-
Caucasians, compared to Caucasians. This group encompasses a diverse set of patients of 
Asian, Hispanic, and Hawaiian/Pacific Islander heritage, with a small number of patients 
representing each group; therefore, further analyses specific to this group were not 
attempted. Finally, as this was not a pre-specified analysis, there were significant differences 
between the three racial groups in terms of number of subjects enrolled, as well as age, time 
post-transplant, type of CNI therapy, and other potentially important confounders.
Conclusions
In summary, we used IMAGE trial data to study whether the increased incidence of adverse 
events after heart transplantation in African Americans and other non-Caucasians may be 
due to differences in the biology of the immune response. We found that, among patients 
receiving tacrolimus, other non-Caucasians had higher GEP scores than the other racial 
groups. African American recipients demonstrated a unique decrease in expression of the 
FLT3 gene in response to higher tacrolimus levels, and expression of this gene was an 
independent predictor of clinical events. Our work thus provides important preliminary data 
for future studies investigating racial differences in alloimmunity. These studies are 
important because, while potent immunosuppressive therapies have improved early survival 
in most racial groups, longer-term survival has improved in Caucasian but not in African 
American or Hispanic recipients, resulting in a marked disparity in outcomes in the current 
era.(28) Enhanced understanding of the biology of such racial disparities may enable us to 
appropriately tailor post-transplant therapies in order to improve outcomes for all patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Event-free progression of the primary outcome, by racial group
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Table 1
Baseline Characteristics of the Study Population, by Racial Group
Characteristic Caucasia
ns
(N=453)
African
Americans
(N=66)
Others
(N=61)
p-value
Age -- yr
  Mean ± StdDev 55.2 ± 12.3 52.1 ± 12.2 47.2 ± 15.1 0.057
  Range 18 – 78 22 – 74 19 – 71
Male sex – no. (%) 375 (80.1) 50 (70.4) 48 (76.2) 0.08
Indication for cardiac transplantation – no. (%)
  Coronary artery disease 218 (46.6) 11 (15.5) 19 (30.2)
  Nonischemic cardiomyopathy 208 (44.4) 52 (73.2) 35 (55.6)
  Valvular heart disease 7 (1.5) 1 (1.4) 2 (3.2)
  Congenital heart disease 15 (3.2) 0 (0) 3 (4.8)
  Graft vasculopathy or retransplantation 2 (0.4) 1 (1.4) 1 (1.6)
  Other 3 (0.6) 1 (1.4) 1 (1.6)
Interval between transplantation and randomization – no. (%)
  6 – 12 months 55 (11.8) 16 (22.5) 14 (22.2) 0.01
  13 – 36 months 317 (67.7) 42 (59.2) 39 (61.9) 0.32
  37 – 60 months 80 (17.1) 8 (11.3) 8 (12.7) 0.3
Cytomegalovirus status – no. (%)
  Donor and recipient positive 170 (36.3) 32 (45.1) 27 (42.9) 0.1
  Donor and recipient negative 81 (17.3) 6 (8.5) 2 (3.2) 0.08
  Donor positive and recipient negative 107 (22.9) 11 (15.5) 11 (17.5) 0.27
  Donor negative and recipient positive 74 (15.8) 14 (19.7) 18 (28.6) 0.38
  Unknown 21 (4.5) 3 (4.2) 3 (4.8)
Use of ventricular assist device before transplantation – no. (%) 91 (19.4) 4 (5.6) 14 (22.2) 0.004
Induction therapy – no. (%)
  Any 260 (55.6) 40 (56.3) 37 (58.7) 0.69
  Muromonab-CD3 4 (0.9) 0 (0) 5 (7.9)
  Antithymocyte globulin 64 (13.7) 4 (5.6) 5 (7.9)
  Basiliximab 79 (16.9) 19 (26.8) 5 (7.9)
  Daclizumab 85 (18.2) 12 (16.9) 23 (36.5)
  Alemtuzumab 19 (4.1) 4 (5.6) 0 (0)
  Other 43 (9.2) 3 (4.2) 10 (15.9)
Immunosuppressive therapy – no. (%)
  Cyclosporine 120 (25.6) 10 (14.1) 26 (41.3) 0.05
  Tacrolimus 338 (72.2) 57 (80.3) 38 (60.3) 0.04
  Mycophenolate mofetil or mycophenolic acid 374 (79.9) 59 (83.1) 47 (74.6) 0.21
  Azathioprine 35 (7.5) 3 (4.2) 3 (4.8) 0.46
  Sirolimus 93 (19.9) 9 (12.7) 15 (23.8) 0.25
  Prednisone 190 (40.6) 33 (46.5) 37 (58.7) 0.23
Medical history after transplantation – no. (%)
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Characteristic Caucasia
ns
(N=453)
African
Americans
(N=66)
Others
(N=61)
p-value
  Hypertension treated with medication 386 (82.5) 57 (80.3) 46 (73) 1
  Diabetes mellitus treated with medication 157 (33.5) 34 (47.9) 29 (46) 0.009
  Renal insufficiency 235 (50.2) 39 (54.9) 21 (33.3) 0.29
  Lipid-lowering drug prescribed 421 (90) 59 (83.1) 57 (90.5) 0.32
Cancer 74 (15.8) 6 (8.5) 4 (6.3) 0.15
Left ventricular ejection fraction at first study visit (%)
  Mean ± StdDev 63.4 ± 6.2 62.3 ± 6.5 63.7 ± 4.6 0.19
Study arm
  Gene expression profiling 232 (49.6) 24 (33.8) 36 (57.1) 0.03
  Endomyocardial biopsy 221 (47.2) 42 (59.2) 25 (39.7) 0.03
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Table 3
Genes comprising the gene expression profile score, with site of expression and putative function
AlloMap Genes
Predominant Source of Expression
in Blood
Role in Immune Activation and
Rejection
ILIR2, ITGAM, FLT3 Monocytes Steroid response
MARCH8, WDR40A Reticulocytes Proliferation and mobilization of erythrocytes
PF4, C6orf25 Platelets Platelet activation
RHOU T cells and monocytes unknown
PDCD1 T cells T cell activation
ITGA4 T cells T cell migration
SEMA7A T cells, B cells, and immature neutrophils unknown
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Table 4
Multivariate model examining predictors of clinical event in African Americans
Predictor p-value
FLT3 Expression 0.005
MARCH8 Expression 0.002
Transplant center 1 center p < 0.05
Age 0.04
Sex 0.05
LVAD Bridge to Transplant 0.03
Study Arm (GEP or EMB) 0.04
Prednisone use < 0.001
Tacrolimus trough level (per 1 ng/ml increase) 0.64
CMV Status (donor +/recipient −) 0.003
Days post transplant 0.004
LVAD: left ventricular assist device; CMV: cytomegalovirus
GEP: gene expression profiling; EMB: endomyocardial biopsy
CMV: cytomegalovirus
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